TY - STD TI - British HIV Association. British HIV Association guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2015. Available at http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf. Accessed 24 Jan 2016. UR - http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf ID - ref1 ER - TY - STD TI - Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 24 Jan 2016. UR - http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf ID - ref2 ER - TY - JOUR AU - Shuter, J. PY - 2008 DA - 2008// TI - Forgiveness of non-adherence to HIV-1 antiretroviral therapy JO - J Antimicrob Chemother VL - 61 UR - https://doi.org/10.1093/jac/dkn020 DO - 10.1093/jac/dkn020 ID - Shuter2008 ER - TY - JOUR AU - Zeldin, R. K. AU - Petruschke, R. A. PY - 2004 DA - 2004// TI - Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients JO - J Antimicrob Chemother VL - 53 UR - https://doi.org/10.1093/jac/dkh029 DO - 10.1093/jac/dkh029 ID - Zeldin2004 ER - TY - JOUR AU - Molina, J. M. AU - Andrade-Villanueva, J. AU - Echevarria, J. AU - Chetchotisakd, P. AU - Corral, J. AU - David, N. PY - 2010 DA - 2010// TI - Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study JO - J Acquir Immune Defic Syndr VL - 53 UR - https://doi.org/10.1097/QAI.0b013e3181c990bf DO - 10.1097/QAI.0b013e3181c990bf ID - Molina2010 ER - TY - JOUR AU - Orkin, C. AU - DeJesus, E. AU - Khanlou, H. AU - Stoehr, A. AU - Supparatpinyo, K. AU - Lathouwers, E. PY - 2013 DA - 2013// TI - Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial JO - HIV Med VL - 14 UR - https://doi.org/10.1111/j.1468-1293.2012.01060.x DO - 10.1111/j.1468-1293.2012.01060.x ID - Orkin2013 ER - TY - JOUR AU - Lennox, J. L. AU - Landovitz, R. J. AU - Ribaudo, H. J. AU - Ofotokun, I. AU - Na, L. H. AU - Godfrey, C. PY - 2014 DA - 2014// TI - A phase III comparative study of the efficacy and tolerability of three non-nucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve HIV-1-infected volunteers: a randomized controlled trial JO - Ann Intern Med VL - 161 UR - https://doi.org/10.7326/M14-1084 DO - 10.7326/M14-1084 ID - Lennox2014 ER - TY - JOUR AU - Mugavero, M. J. AU - May, M. AU - Ribaudo, H. J. AU - Gulick, R. M. AU - Riddler, S. A. AU - Haubrich, R. PY - 2011 DA - 2011// TI - Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study JO - J Acquir Immune Defic Syndr VL - 58 UR - https://doi.org/10.1097/QAI.0b013e318230372e DO - 10.1097/QAI.0b013e318230372e ID - Mugavero2011 ER - TY - JOUR AU - Cuzin, L. AU - Pugliese, P. AU - Allavena, C. AU - Katlama, C. AU - Cotte, L. AU - Cheret, A. PY - 2015 DA - 2015// TI - Comparative effectiveness of first antiretroviral regimens in clinical practice using a causal approach JO - Medicine VL - 95 UR - https://doi.org/10.1097/MD.0000000000001668 DO - 10.1097/MD.0000000000001668 ID - Cuzin2015 ER - TY - JOUR AU - Johnston, S. S. AU - Juday, T. AU - Esker, S. AU - Espindle, D. AU - Chu, B. C. AU - Hebden, T. PY - 2013 DA - 2013// TI - Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy JO - Value Health VL - 16 UR - https://doi.org/10.1016/j.jval.2012.10.021 DO - 10.1016/j.jval.2012.10.021 ID - Johnston2013 ER - TY - JOUR AU - Nishijima, T. AU - Hamada, Y. AU - Watanabe, K. AU - Komatsu, H. AU - Kinai, E. AU - Tsukada, K. PY - 2013 DA - 2013// TI - Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0077268 DO - 10.1371/journal.pone.0077268 ID - Nishijima2013 ER - TY - JOUR AU - Aberg, J. A. AU - Tebas, P. AU - Overton, E. T. AU - Gupta, S. K. AU - Sax, P. E. AU - Landay, A. PY - 2012 DA - 2012// TI - Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks JO - AIDS Res Hum Retrovir VL - 28 UR - https://doi.org/10.1089/aid.2011.0327 DO - 10.1089/aid.2011.0327 ID - Aberg2012 ER - TY - JOUR AU - Palmer, A. AU - Klein, M. AU - Raboud, J. AU - Cooper, C. AU - Hosein, S. AU - Loutfy, M. PY - 2011 DA - 2011// TI - Cohort profile: the Canadian Observational Cohort Collaboration JO - Int J Epidemiol VL - 40 UR - https://doi.org/10.1093/ije/dyp393 DO - 10.1093/ije/dyp393 ID - Palmer2011 ER - TY - JOUR AU - Gray, R. J. PY - 1988 DA - 1988// TI - A class of k-sample tests for comparing the cumulative incidence of a competing risk JO - Ann Stat VL - 16 UR - https://doi.org/10.1214/aos/1176350951 DO - 10.1214/aos/1176350951 ID - Gray1988 ER - TY - JOUR AU - Fine, J. P. AU - Gray, R. J. PY - 1999 DA - 1999// TI - A proportional hazards model for the subdistribution of a competing risk JO - J Am Stat Assoc VL - 94 UR - https://doi.org/10.1080/01621459.1999.10474144 DO - 10.1080/01621459.1999.10474144 ID - Fine1999 ER - TY - STD TI - Bartlett JW, Taylor JM. Missing covariates in competing risk analysis. Biostatistics. 2016;17:751-63. ID - ref16 ER - TY - JOUR AU - Rubin, D. B. PY - 1976 DA - 1976// TI - Inference and missing data JO - Biometrika VL - 63 UR - https://doi.org/10.1093/biomet/63.3.581 DO - 10.1093/biomet/63.3.581 ID - Rubin1976 ER - TY - STD TI - Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987. ID - ref18 ER -